Chaperonin 10 immunosuppression
The invention is directed to the use of cpnl0 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease.
1. A pharmaceutical composition comprising:
a pharmaceutically-effective amount of cpn10 comprising the amino acid sequence set forth in FIG. 1 (SEQ ID NO:1), and
a pharmaceutically-acceptable carrier, excipient or diluent.
2. An isolated polypeptide comprising the amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).